Contrasting Tauriga Sciences (OTCMKTS:TAUG) & Biodesix (NASDAQ:BDSX)

Biodesix (NASDAQ:BDSX) and Tauriga Sciences (OTCMKTS:TAUG) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Profitability

This table compares Biodesix and Tauriga Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biodesix	-39.85%	-1,760.83%	-40.28%
Tauriga Sciences	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and price targets for Biodesix and Tauriga Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1	0	5	0	2.67
Tauriga Sciences	0	0	0	0	0.00

Biodesix currently has a consensus price target of $32.50, indicating a potential upside of 124.14%. Given Biodesix’s stronger consensus rating and higher probable upside, research analysts plainly believe Biodesix is more favorable than Tauriga Sciences.

Institutional & Insider Ownership

21.0% of Biodesix shares are owned by institutional investors. 30.1% of Biodesix shares are owned by company insiders. Comparatively, 3.5% of Tauriga Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Biodesix and Tauriga Sciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50 million	1.62	-$35.26 million	($4.85)	-2.99
Tauriga Sciences	N/A	N/A	N/A	N/A	N/A

Tauriga Sciences has lower revenue, but higher earnings than Biodesix.

Summary

Biodesix beats Tauriga Sciences on 6 of the 9 factors compared between the two stocks.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

About Tauriga Sciences

Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea products; and skin care products include CBD facemasks; CBD daily moisturizer; CBD anti-wrinkle dream, hand, and foot cream with hemp seed oil; CBD massage and body oil; CBD body revive roll-on; CBD transdermal patch; and CBD body spray. In addition, the company offers rainbow deluxe sampler pack, CBD non-GMO dietary supplements, and CBD scented bath bombs. It sells its products through e-commerce, distributors, and wholesale channels. The company has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in Wappingers Falls, New York.